In recent, Shanghai Epiprobe Biotechnology Co., Ltd. (refer as "Epiprobe") announced that it had completed nearly RMB 100 million in Series B financing, which is jointly invested by industrial capital, government investment platforms and listed company Yiyi Shares (SZ:001206).
Founded in 2018, Epiprobe, as an upholder and pioneer of early pan-cancer screening, is a high-tech enterprise focusing on cancer molecular diagnosis and precision medicine industry. Building on the top team of epigenetics experts and profound academic accumulation, Epiprobe explores the field of cancer detection, upholds the vision of "keeping everyone away from cancer," committed to early detection, early diagnosis and early treatment of cancer, thereby improving the survival rate of cancer patients to enhance the health of the whole population.
After digging for 20 years, Epiprobe's core team independently discovered a series of cancer Aligned General Methylated Epiprobes (TAGMe), which are universal in various cancers, thus significantly expanding the application field.
Regarding detection technology, pyrosequencing is traditionally deemed as the "gold standard" for methylation detection, which nevertheless relies on bisulfite conversion, but features the shortcomings like unstable conversion efficiency, easy DNA degradation, high requirements for operators, and dependence on valuable instruments. These shortages limit its application. Epiprobe, through making technical breakthroughs, independently has developed an innovative methylation detection technology - Me-qPCR without bisulfite treatment, which decreases the cost and improve the detection stability and clinical operability, making the detection simple and easy.
Epiprobe, centering on the company's core pan-cancer markers and methylation detection methods, has applied over 50 domestic and international patents, and has obtained authorizations to establish a solid patent upholder.
Currently, Epiprobe has worked closely with over 40 top hospitals in China, including Zhongshan Hospital, International Peace Maternity and Child Health Hospital, and Changhai Hospital etc, and has implemented extensive product layout in female reproductive tract cancers (including cervical cancer, endometrial cancer), urothelial cancer (including bladder cancer, ureteral cancer, renal pelvis cancer), lung cancer, thyroid cancer, hematological cancer and other cancers. The double-blind validation has been implemented in 70,000 clinical samples with total of 25 types of cancer.
Among the products, for female reproductive tract cancer detection products, the double-blind validation has been implemented in over 40,000 clinical samples, and a series of research results have been published in internationally renowned academic journals like Cancer Research, Clinical and Translational Medicine, and multiple large-scale multi-center clinical trials are being implemented. As the R&D progress advances and the resources constantly increase, the company's product pipeline is steadily increasing.
Ms. Hua Lin, CEO of Epiprobe noted that: “It's our great honor to be recognized and supported by excellent industrial capitals. Epiprobe is characterized by its profound academic accumulation, unique technology, and solid clinical research, which has won the trust of many parties. Over the past four years, the company's team and operations have improved increasingly. In the coming days, we'll spare no effort to invite more like-minded partners to cooperate with and work together, thereby constantly promoting the R&D and registration application process, as well as providing clinicians and patients with the best quality cancer testing services and products.”
Post time: Apr-11-2022